rethinkPeptides Search
Menu
Study breakdown

Neuropeptides Generate Tolerogenic Dendritic Cells for Treating Autoimmune Disease

evidence
The takeaway

Neuropeptides (VIP, PACAP, alpha-MSH) generate tolerogenic dendritic cells that suppress autoimmune responses through Treg induction — a practical immunotherapy approach using the neuroimmune system.

Key finding

Neuropeptides (VIP, PACAP, alpha-MSH) generate tolerogenic dendritic cells that suppress autoimmune responses through Treg induction — a practical imm

What the researchers found

Neuropeptides (VIP, PACAP, alpha-MSH) generate tolerogenic dendritic cells that suppress autoimmune responses through Treg induction — a practical immunotherapy approach using the neuroimmune system.

Why it matters

Relevant for peptide research.

How the study worked

research study.

What this study cannot tell us

See abstract.

How to read the evidence

emerging evidence.

When this study was published

Published in 2009.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.

Common questions

What was studied?
Neuropeptides Generate Tolerogenic Dendritic Cells for Treating Autoimmune Disease
What was found?
Neuropeptides (VIP, PACAP, alpha-MSH) generate tolerogenic dendritic cells that suppress autoimmune responses through Treg induction — a practical immunotherapy approach using the neuroimmune system.

Read the original research

Generating tolerogenic dendritic cells with neuropeptides.

Human immunology, 70(5), 300-7

Citation

Delgado, Mario. (2009). Generating tolerogenic dendritic cells with neuropeptides.. Human immunology, 70(5), 300-7.